日本語
トップページ

Division of Innovative Cancer Therapy

Head TODO Tomoki
Location Second Building 4F
Website

Division of Innovative Cancer Therapy website (Japanese only) Open a new window

Annual Report

Annual Report 2019(PDF:818KB)

Activities

We have been focusing on the development of innovative cancer treatment, especially with genetically-engineered viruses which can kill the tumor cells without affecting normal cells. G47Δ, a triple-mutated herpes simplex virus type I (HSV-1), exhibits potent therapeutic efficacy with enhanced safety. G47Δ has been used in several clinical trials that are ongoing. We are also seeking next generation therapeutics utilizng G47Δ and patient-derived glioma cell lines to overcome resistance, recurrence and metastasis often seen in the clinical settings.

Member List